Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-533-4 | CAS number: 142-30-3
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP non-guideline study, available as unpublished report, limitations in design and/or reporting but otherwise adequate for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 973
- Report date:
- 1973
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- BASF internal method: Several groups of mice per sex and dose were injected in the peritoneal cavity with preparations of the test substance in CMC. Mice were necropised after the observation period of 7 days.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- 2,5-dimethylhexyne-2,5-diol
- EC Number:
- 205-533-4
- EC Name:
- 2,5-dimethylhexyne-2,5-diol
- Cas Number:
- 142-30-3
- Molecular formula:
- C8H14O2
- IUPAC Name:
- 2,5-dimethylhex-3-yne-2,5-diol
- Details on test material:
- - Name of test material (as cited in study report): Dimethylhexindiol
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- not specified
- Sex:
- not specified
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- CMC (carboxymethyl cellulose)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 800 mg/kg bw
- Based on:
- test mat.
- Clinical signs:
- Dyspnea, staggering, tonic and clonic convulsions, twitching, tremors, lying on the stomach and in the lateral position, apathy, poor general health, and a yellower urine than usual were observed.
- Gross pathology:
- No intra-abdominal substance residues were observed.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
